Literature DB >> 19357396

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

Claude Preudhomme1, Aline Renneville, Violaine Bourdon, Nathalie Philippe, Catherine Roche-Lestienne, Nicolas Boissel, Nathalie Dhedin, Jean-Marie André, Pascale Cornillet-Lefebvre, André Baruchel, Marie-Joelle Mozziconacci, Hagay Sobol.   

Abstract

Familial platelet disorder (FPD), a rare autosomal dominant disorder characterized by quantitative and qualitative platelet abnormalities, is considered as a model of genetic predisposition to acute myeloid leukemia (AML). So far, monoallelic RUNX1 germline mutations have been found in 19 of 20 families with reported FPD, and the analysis of blast cells from only 5 patients at acute leukemia (AL) stage has shown no additional RUNX1 abnormality. Here, we performed RUNX1 analysis at constitutional and somatic levels in 8 persons with FPD who developed AL from 4 independent families. In addition to the germline RUNX1 mutation, we identified a second RUNX1 alteration in 6 AML cases (acquired point mutations in 4 cases and duplication of the altered RUNX1 allele associated with acquired trisomy 21 in 2 other cases). Although haploinsufficiency of RUNX1 causes FPD, our findings suggest that a second genetic event involving RUNX1 is often associated with progression to AML.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19357396     DOI: 10.1182/blood-2008-07-168260

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  66 in total

1.  Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Lynn R Goldin; Sigurdur Y Kristinsson; Xueying Sharon Liang; Asa R Derolf; Ola Landgren; Magnus Björkholm
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia.

Authors:  I Antony-Debré; N Duployez; M Bucci; S Geffroy; J-B Micol; A Renneville; N Boissel; N Dhédin; D Réa; B Nelken; C Berthon; T Leblanc; M-J Mozziconacci; R Favier; P G Heller; O Abdel-Wahab; H Raslova; V Latger-Cannard; C Preudhomme
Journal:  Leukemia       Date:  2015-08-28       Impact factor: 11.528

3.  Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.

Authors:  Daria V Babushok; Monica Bessler; Timothy S Olson
Journal:  Leuk Lymphoma       Date:  2015-12-23

4.  Clinical utility gene card for: Familial platelet disorder with associated myeloid malignancies.

Authors:  Tim Ripperger; Kiran Tawana; Christian Kratz; Brigitte Schlegelberger; Jude Fitzgibbon; Doris Steinemann
Journal:  Eur J Hum Genet       Date:  2016-01-27       Impact factor: 4.246

5.  Recurrent somatic JAK-STAT pathway variants within a RUNX1-mutated pedigree.

Authors:  Kiran Tawana; Jun Wang; Péter A Király; Krisztián Kállay; Gábor Benyó; Marianna Zombori; Judit Csomor; Ahad Al Seraihi; Ana Rio-Machin; András Matolcsy; Claude Chelala; Jamie Cavenagh; Jude Fitzgibbon; Csaba Bödör
Journal:  Eur J Hum Genet       Date:  2017-05-17       Impact factor: 4.246

6.  Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia.

Authors:  Iléana Antony-Debré; Vladimir T Manchev; Nathalie Balayn; Dominique Bluteau; Cécile Tomowiak; Céline Legrand; Thierry Langlois; Olivia Bawa; Lucie Tosca; Gérard Tachdjian; Bruno Leheup; Najet Debili; Isabelle Plo; Jason A Mills; Deborah L French; Mitchell J Weiss; Eric Solary; Remi Favier; William Vainchenker; Hana Raslova
Journal:  Blood       Date:  2014-12-09       Impact factor: 22.113

7.  Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis.

Authors:  Bindya Jacob; Motomi Osato; Namiko Yamashita; Chelsia Qiuxia Wang; Ichiro Taniuchi; Dan R Littman; Norio Asou; Yoshiaki Ito
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

Review 8.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

Review 9.  Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations.

Authors:  Allison H West; Lucy A Godley; Jane E Churpek
Journal:  Ann N Y Acad Sci       Date:  2014-01-27       Impact factor: 5.691

Review 10.  A role for RUNX1 in hematopoiesis and myeloid leukemia.

Authors:  Motoshi Ichikawa; Akihide Yoshimi; Masahiro Nakagawa; Nahoko Nishimoto; Naoko Watanabe-Okochi; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.